STAT+: Judge rules against compounding group; Hims’ shares fall

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hi there. Today, we unpack Marty Makary’s Senate  confirmation hearing, see a new ruling against GLP-1 compounders, examine the effects of the NIH patent freeze, and explore the tumultuous biotech job market.

The need-to-know this morning

• Nimbus Therapeutics said CEO Jeb Keiper is stepping down immediately as part of a planned transition. The company named Abbas Kazimi, its chief business officer since 2020, as Keiper’s successor.

Makary FDA hearing: More MAHA focus than regulatory policy

Marty Makary’s Senate confirmation hearing to be FDA commissioner went rather smoothly. He wasn’t pressed much on core regulatory issues; four senators asked about the abortion drug mifepristone, and just one asked about accelerated approvals and rare disease drugs. There were no questions on GLP-1 drug shortages, FDA’s regulation of AI, or lab-developed tests — all key issues for the agency these days.

Continue to STAT+ to read the full story…